Board summary
Key figures
30,505
Registered population
56.3% aged 18–64
27.1%
Aged 65+
ICB 20.0% · England 17.9%
3.4%
Ethnic minority (non-White)
1.4% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 30.6% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
5,383
Hypertension register
+3.82% in 3 yrs · England +5.60%
233
SMI register
21.8% of West Lancashire's
538
COPD register
Reviews +21.35% in 3 yrs
Forecast to 2030
5,988
Hypertension patients, 2030
+605 on today
54.4%
QRISK ≥20% on statins, 2030
+1.53pp over 3 yrs
6.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy trails comparators.
Only 51.2% of patients with QRISK ≥ 20% receive lipid-lowering therapy (England 63.6%), alongside 66.3% hypertension control (West Lancashire 74.1%), which may reflect titration.
Asthma and SMI reviews lag borough.
Asthma annual reviews sit at 63.8% (leaving about 750 unreviewed) and SMI blood pressure checks at 77.5% (West Lancashire 84.9%), suggesting recall gaps.
Age-five vaccination exceeds 95.0% target.
MMR dose 2 and 4-in-1 booster coverage at age 5 both reach 95.5% in Q1 2025/26, surpassing England (82.8% and 80.9%) and the 95.0%.
Population, age and ethnicity
An older population with 27.1% aged 65+ could drive higher primary care demand
Ormskirk PCN has 30,505 registered patients. Service planning is shaped by an older demographic: 27.1% (8,274 patients) are aged 65+, compared to 22.8% in West Lancashire, 20.0% in the ICB, and 17.9% in England. Those aged 18-64 represent 56.3% (17,169 patients; West Lancashire 59.3%, ICB 60.4%, England 62.7%), and aged 0-17 represent 16.6% (5,062 patients; West Lancashire 17.9%, ICB 19.6%, England 19.6%). Census usual-resident ethnicity shows 96.6% White (West Lancashire 96.9%, ICB 87.8%, England 81.1%) and a 3.4% non-White ethnic minority share (Asian 1.4%, Mixed 1.4%, Black 0.4%, Other 0.2%).
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are West Lancashire local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (West Lancashire LA) | 2,016 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (West Lancashire LA) | 995 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (West Lancashire LA) | 11.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is low across Ormskirk PCN, with zero registered patients in Core20 areas
Ormskirk PCN records an average IMD decile of 7.8, compared to 6.2 in West Lancashire, 5.0 in the ICB, and 5.5 in England. Across the PCN, 0.0% of registered patients live in Core20 areas (West Lancashire 16.3%, ICB 30.6%, England 21.0%), yielding 0 estimated Core20 patients. However, area-level affluence can mask clinical vulnerability: among 233 patients on the severe mental illness register, blood pressure checks reach 77.5% (West Lancashire 84.9%, England 83.4%). Place-based Core20 outreach will not address local inequalities, so the PCN should target condition-specific clinical cohorts.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
233
SMI register
0.77% recorded prevalence
114
Learning disability register
0.38% recorded prevalence
13
Care homes, 652 beds
In the PCN catchment
10.0%
Provide unpaid care
West Lancashire, Census 2021
Inclusion-health registers record 233 severe mental illness patients (0.8% vs West Lancashire 0.9%, ICB 1.2%, England 1.0%) and 114 learning disability patients (0.4% vs West Lancashire 0.5%, ICB 0.6%, England 0.6%). The PCN catchment includes 13 care homes with 652 beds. Borough data records 10.0% unpaid care and 9 rough sleepers, which cannot be extrapolated to PCN lists.
Severe mental illness: physical health checks
SMI physical health checks trail West Lancashire: blood pressure recording is 77.5% (vs 84.9%), BMI is 75.0% (vs 84.0%), and alcohol status is 70.5% (vs 83.7%). Lower recording could indicate systematic recall gaps, testable by register audit.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,383
Hypertension register
+3.82%
Register growth, 3 yrs
West Lancashire +5.26% · England +5.60%
+1.99pp
BP control, under 80
≤140/90 · +5.49pp aged 80+
+605
More patients by 2030
Forecast 5,988 (19.12%)
Hypertension case-finding and control
Hypertension recorded prevalence is 17.7% (5,383 patients), compared with 18.2% in West Lancashire, 17.2% in the ICB, and 15.2% in England. While 87.4% of patients have a recent blood pressure reading (West Lancashire 90.1%, England 90.0%), treatment to target is 66.3% (West Lancashire 74.1%, England 70.3%). In patients aged under 80, control to <= 140/90 mmHg is 61.7% (West Lancashire 71.1%, England 67.8%), dropping to 53.1% at Ormskirk Medical Practice. Lower blood pressure control compared with West Lancashire and England may indicate review or titration gaps, which clinical audits could test.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy stand at 51.2%, behind West Lancashire (58.0%) and England (63.6%). Among patients with CKD, therapy coverage is 60.6% against 70.3% nationally. Trailing national lipid coverage could leave high-risk cohorts under-protected, which targeted therapy reviews could test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 53,202 | £1.70 | £1.64 | £1.86 | £90,443 |
| Cardiovascular (all), 2025 | 87,175 | £4.37 | £3.38 | £3.33 | £380,955 |
In 2026, lipid-modifying drugs cost £1.70 per item across 53,202 items, compared with £1.75 in West Lancashire, £1.64 in the ICB, and £1.86 in England. PCN spend was £8,512 less than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+21.22%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.37%
Asthma prevalence, PCN 3-yr % change
Recorded asthma prevalence is 7.2% (2,070 patients), with annual reviews at 63.8% (West Lancashire 70.0%, England 65.7%), leaving about 750 patients unreviewed despite a 3-year relative increase of +21.2% (England +4.4%). Asthma management prescribing for ages 5-19 is 1,995 items per 1,000 (England 1,488). COPD prevalence is 1.8% (538 patients), where 12-month reviews rose +21.4% to 79.0% (West Lancashire 83.4%, England 76.4%). Slower review completion alongside elevated youth prescribing could indicate routine monitoring gaps, which clinical audits could test.
Cancer register and children's immunisation
Cancer QOF prevalence is 5.4% (1,641 patients), exceeding West Lancashire (4.7%) and England (3.8%). In childhood immunisations (Q1 2025/26), 12-month 6-in-1 coverage is 91.2% (ICB 90.3%, England 91.0%), below the 95.0% target by 3.8 pp. By age 5, MMR dose 1 reaches 100.0% while dose 2 is 95.5% (a 4.5 pp difference). Timely first-year primary vaccination requires focused attention.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of staged cancers across NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2 (4,642 of 8,863 known-stage cancers; not published at PCN level), trailing England (55.3%) and 22.6 pp below the 75.0% national ambition. Known stage was recorded for 74.6% of registered cancers (8,863 of 11,883). Reaching the 75.0% ambition requires about 2,010 additional early-stage diagnoses annually across the ICB, where early-stage share fell 1.2 pp from 2013 to 2022. Locally, PCN cervical screening is 71.8% (England 66.8%) but fell 2.6% over three years (England -1.0%), with Ormskirk Medical Practice at 68.0%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Liverpool University Hospitals NHS Foundation Trust achieved 73.3% on the 62-day referral to treatment standard (standard 85.0%), trailing Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust (76.8%), and the ICB (73.6%), though above England (71.2%). On the 28-day faster diagnosis standard, the trust reached 75.5% (standard 75.0%), behind the ICB (78.4%) and England (79.3%). For diagnostics, 33.1% of colonoscopy and 46.5% of flexi sigmoidoscopy patients at the trust waited 6+ weeks, exceeding England (30.8% and 32.1%).
| Pathways within standard (%) | Liverpool | Mersey and West Lancashire | Wrightington, Wigan and Leigh | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.47 | 72.39 | 82.80 | 78.39 | 79.32 |
| 31-day treatment (96%) | 90.51 | 95.46 | 89.04 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.26 | 77.96 | 76.78 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Liverpool | Mersey and West Lancashire | Wrightington, Wigan and Leigh | England |
|---|---|---|---|---|
| MRI | 6.42 | 14.04 | 0.49 | 21.40 |
| CT | 0.71 | 13.08 | 7.78 | 9.92 |
| Echocardiography | 12.55 | 34.88 | 24.37 | 28.48 |
| Colonoscopy | 33.14 | 18.04 | 6.10 | 30.83 |
| Gastroscopy | 44.99 | 18.17 | 12.54 | 29.02 |
| All 15 DM01 tests | 11.50 | 21.17 | 14.36 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026, adults aged 65 and over accounted for 56.9% of all community service contacts among West Lancashire residents (72,000 of 126,445 contacts). This older-age concentration is consistent with borough-wide community care reliance, though activity is published for local authority residents rather than registered PCN cohorts.
Practice variation and patient experience
Practice vaccination achievement spans 36.3 pp and overall patient experience spans 20.9 pp
In 2025/26, QOF overall achievement was 87.6% at Ormskirk Medical Practice. QOF overall achievement was 97.3% at Parkgate Surgery. The England comparator for QOF overall achievement was 92.5%. For QOF vaccination and immunisation-domain achievement, Aughton Surgery achieved 48.8%. In the same domain, Ormskirk Medical Practice achieved 85.1%. The England comparator for vaccination and immunisation achievement was 55.2%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Aughton Surgery | 105 | 0.0 | 72.7% | 70.6% | 92.8% |
| The Elms Practice | 105 | 0.0 | 71.9% | 64.1% | 90.7% |
| Ormskirk Medical | 137 | 0.0 | 57.2% | 70.2% | 80.7% |
| Parkgate Surgery | 122 | 0.0 | 65.5% | 76.2% | 71.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven of 25 tracked measures trail England's three-year progress, led by screening
Across 25 tracked measures, 11 trail England's three-year change. The widest relative lags are in breast screening, which fell 0.3% (England +8.4%), and heart failure reviews, which grew +3.1% (England +8.7%), leaving current heart failure review coverage at 73.5% (England 78.5%). Severe mental illness blood pressure checks fell 1.1 pp (England +4.4 pp). In contrast, three-year review gains were strong in COPD (+21.4% vs England +2.8%) and asthma (+21.2% vs England +4.4%), alongside blood pressure control in patients aged 80 and over (+7.5% vs England +2.2%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Breast screening (53-70)
Heart failure reviews
BP check (SMI)
Alcohol record (psychosis)
QRISK statin treatment
COPD reviews
Asthma reviews
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | West Lancashire | Asset | PCN | West Lancashire |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (652 beds) | n/a | Schools (catchment) | 36 | n/a |
| Children's centres | 1 | 7 | Places of worship | 22 | 79 |
| Libraries | 1 | 4 | Primary schools (LA maintained) | 16 | 47 |
| Primary academies | n/a | 5 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall
Asthma annual review coverage is 63.8% across 2,070 register patients, below 70.0% in West Lancashire and 65.7% in England, leaving about 750 patients without a recorded 12-month review. For discussion: run a single-template asthma recall prioritising patients on repeat inhalers and offering after-school or holiday review slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
SMI physical health check recall
Across 233 severe mental illness register patients, 12-month blood pressure recording is 77.5% (down 1.1 pp over three years vs England +4.4 pp), trailing West Lancashire (84.9%) and England (83.4%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Hypertension and lipid titration review
Among 5,383 hypertension patients (17.7%; gap range -737 to +174), treatment to target is 66.3% (West Lancashire 74.1%, England 70.3%) and under-80 control is 61.7% (Ormskirk Medical Practice 53.1%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register validation (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Severe mental illness check recall (p3) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| SMI physical health recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration recall (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Infant immunisation call and recall (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice access and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · SMI physical health check recall (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Hypertension and lipid titration review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
